Sugi Predict

Sugi Predict / Compounds / SCHEMBL1703769

SCHEMBL1703769

SCHEMBL1703769

CN1CCC(Cn2cc(N)cn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ ALOX15 P16050 1/20 0.43
▸ GAA P10253 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NCF1 P14598 1/20 0.40
▸ HRH3 Q9Y5N1 2/20 0.39
▸ HRH4 Q9H3N8 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ KLKB1 P03952 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PI4KA P42356 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ MAPK7 Q13164 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ FGFR4 P22455 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3259744 0.86 PIK3CD (0.46) HDAC1HDAC2KLKB1PIK3CDPIK3CA
Hydrochloric Acid SCHEMBL17003092 0.84 MAPT (0.45) HDAC1HDAC2HRH4KLKB1PIK3CD
SCHEMBL31361594 0.83 KLKB1 (0.41) HDAC1HDAC2ALOX15HRH3CHRM3
SCHEMBL1665196 0.83 KLKB1 (0.41) HDAC1HDAC2ALOX15HRH3CHRM3
SCHEMBL31361733 0.83 KLKB1 (0.41) HDAC1HDAC2ALOX15HRH3CHRM3
SCHEMBL23623150 0.83 KLKB1 (0.44) HDAC1HDAC2HRH4KLKB1PIK3CD
SCHEMBL23212539 0.83 KLKB1 (0.46) HDAC1HDAC2HRH4KLKB1PIK3CD
SCHEMBL12093358 0.82 HDAC1 (0.43) HDAC1HDAC2ALOX15NCF1HRH3
SCHEMBL4192158 0.81 KLKB1 (0.48) HDAC1HDAC2HRH4KLKB1PIK3CD
Cyanide SCHEMBL27964377 0.81 PIK3CD (0.43) HDAC1HDAC2KLKB1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 — — US disclosed
WO-2025017116-A1 PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2025-01-23 — — WO disclosed
EP-4186894-B1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-12-04 — — EP disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
EP-4186894-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2023-05-31 — — EP disclosed
EP-4186894-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2023-05-31 — — EP disclosed
CN-113620950-A Carboxamide derivatives useful as RSK inhibitors 凤凰分子设计公司 2021-11-09 — — CN disclosed
CN-109071542-B Carboxamide derivatives useful as RSK inhibitors 凤凰分子设计公司 2021-07-20 — — CN disclosed
WO-2017141116-A1 CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS PHOENIX MOLECULAR DESIGNS (CA) 2017-08-24 — — WO disclosed
US-20170240549-A1 TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS PHOENIX MOLECULAR DESIGNS (CA) 2017-08-24 — — US disclosed
US-20170240549-A1 TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS PHOENIX MOLECULAR DESIGNS (CA) 2017-08-24 — — US disclosed
EP-3194390-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 Cancer Research Technology Ltd (GB) 2017-07-26 — — EP disclosed
US-20160102094-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C IGNYTA, INC. (US) 2016-04-14 — — US disclosed
WO-2016042341-A1 PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-03-24 — — WO disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB HDAC1 3999/4885HDAC2 3396/4885ALOX15 3879/4885
US-12630530-B2 FGFR inhibitor compound and use thereof FGFR3, FGFR1, FGFR4 HDAC1 1161/4885HDAC2 1386/4885ALOX15 2773/4885
US-20160102094-A1 Azaquinazoline Inhibitors of Atypical Protein Kinase C PRKCQ, PRKCZ, PRKCE HDAC1 837/4885HDAC2 1910/4885ALOX15 4828/4885
US-20170240549-A1 TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS RPS6KA5, RPS6KA2, RPS6KA1 HDAC1 633/4885HDAC2 706/4885ALOX15 3740/4885
US-20230192656-A1 FGFR INHIBITOR COMPOUND AND USE THEREOF FGFR3, FGFR1, FGFR4 HDAC1 769/4885HDAC2 1261/4885ALOX15 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.